Skip to content
MRD Watch

Wednesday, November 18, 2026

Subscribe
Sponsor this briefing. One site and newsletter slot, $250/week.

Briefing

Circulating tumor DNA-guided de-escalation or escalation of adjuvant therapy in high-risk stage II and stage III colon cancer: the phase 2 PEGASUS trial.

Of 135 people, 26% were ctDNA-positive after surgery. The primary endpoint in ctDNA-negative people was not met (2-year relapse-free rate 88%, below the 92% threshold).

Nature CancerPubMed 42736431DOI 10.1038/s43018-026-01237-9